Trial Profile
A Randomized Phase II Study of Pazopanib and Weekly Paclitaxel in Patients With Platinum Resistant/Refractory Ovarian Cancer Who Relapse During Bevacizumab Maintenance
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Aug 2022
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary) ; Paclitaxel
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms TAPAZ
- 25 Jul 2022 Results published in the Gynecologic Oncology
- 09 Feb 2021 Status changed from active, no longer recruiting to completed.
- 21 Sep 2020 Primary endpoint (Progression free survival (PFS)) has not been met, according to results presented at the 45th European Society for Medical Oncology Congress